The purpose of this study is to obtain reliable and interpretable data to inform future
trials regarding our hypothesis that a novel, liquid aspirin formulation can mitigate COVID
-19 associated coagulopathy (CAC) . The potential impact is to reduce COVID-19 related
hospitalization within 30 days of diagnosis due to (1) pulmonary events including respiratory
failure; (2) cardiac events including myocardial infarction and myocarditis (3) venous or
arterial thrombotic events; (4) acute renal insufficiency or failure.
Phase:
Phase 2
Details
Lead Sponsor:
Louisiana State University Health Sciences Center in New Orleans